Category Archives: Northwestern

Carbon dioxide can reduce belly fat – Study

I had misgivings about carrying this item because I think the idea is total health and a long life, not superficial quick fixes. But this seems a fascinating concept and it originated from my old Alma Mater (in a sense) – Northwestern University. I taught journalism in the grad school there for a couple of years. Eat less; move more; live longer remains the mantra of this blog.

While the technique is safe it needs to be optimized for longer-lasting results.

clear water drops

Photo by Anthony on Pexels.com

Marla Paul, writing in Northwestern Now, reported the following:

The first randomized, controlled trial testing carbon dioxide gas injections (carboxytherapy) to reduce belly fat found the new technique eliminates fat around the stomach. However, the changes were modest and did not result in long-term fat reduction, according to the Northwestern Medicine study.

“Carboxytherapy could potentially be a new and effective means of fat reduction,” said lead author Dr. Murad Alam, vice chair of dermatology at Northwestern University Feinberg School of Medicine and a Northwestern Medicine physician. “It still needs to be optimized, though, so it’s long lasting.” Continue reading

Leave a comment

Filed under abdominal fat, belly fat, bellyfat, body fat, fat, Northwestern

Amish have internal ‘fountain of youth’ – Study

The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.

An experimental “longevity” drug that recreates the effect of the mutation is now being tested in human trials to see if it provides protection against some aging-related illnesses.

Indiana Amish kindred (immediate family and relatives) with the mutation live more than 10 percent longer and have 10 percent longer telomeres (a protective cap at the end of our chromosomes that is a biological marker of aging) compared to Amish kindred members who don’t have the mutation, reports the new Northwestern study. (my emphasis)

Amish with this mutation also have significantly less diabetes and lower fasting insulin levels. A composite measure that reflects vascular age also is lower — indicative of retained flexibility in blood vessels in the carriers of the mutation — than those who don’t have the mutation, the research also found.

The paper was published Nov. 15 in the journal Science Advances.

These Amish individuals have very low levels of PAI-1 (plasminogen activator inhibitor,) a protein that comprises part of a “molecular fingerprint” related to aging or senescence of cells. It was previously known that PAI-1 was related to aging in animals but unclear how it affected aging in humans.

“The findings astonished us because of the consistency of the anti-aging benefits across multiple body systems,” said Dr. Douglas Vaughan, the lead author of the paper who has been studying PAI-1 for almost 30 years.

Vaughan, a cardiologist, is the Irving S. Cutter Professor and chairman of medicine at Northwestern University Feinberg School of Medicine and Northwestern Medicine.

“For the first time we are seeing a molecular marker of aging (telomere length), a metabolic marker of aging (fasting insulin levels) and a cardiovascular marker of aging (blood pressure and blood vessel stiffness) all tracking in the same direction in that these individuals were generally protected from age-related changes,” Vaughan said. “That played out in them having a longer lifespan. Not only do they live longer, they live healthier. It’s a desirable form of longevity. It’s their ‘health span.’”

“Longevity” drug developed by Northwestern and Tohoku University

Northwestern has partnered with Tohoku University in Japanin the development and testing of an oral drug, TM5614, that inhibits the action of PAI-1. The drug has already been tested in a phase 1 trial in Japan and is now in phase 2 trials there. Northwestern will apply for FDA approval to start an early phase trial in the U.S., possibly to begin within the next six months.

The proposed Northwestern trial will investigate the effects of the new drug on insulin sensitivity on individuals with type 2 diabetes and obesity because of the mutation’s effect on insulin levels in the Amish.

A mutation confers longevity

In the new study, Northwestern scientists looked at individuals who had one mutant copy of the gene, rendering their level of PAI-1 about half the level of kindred with two normal copies. Continue reading

Leave a comment

Filed under aging, Amish, living longer, longevity, Northwestern, successful aging, telomeres